Phathom Pharmaceuticals Plunges 14.00% to Record Low

Phathom Pharmaceuticals (PHAT) experienced a significant decline today, with its share price dropping to a record low, marking an intraday decrease of 14.00%.

Phathom Pharmaceuticals has received a "Strong Buy" rating from analysts, with a price target consensus of $21.43, suggesting a potential upside of 319.4% from current levels. This optimistic outlook is supported by recent increases in holdings by large investors, such as Jennison Associates LLC, which has grown its stake in the company by 20.4%.

Despite the positive analyst sentiment, the company's P/E ratio stands at -0.73, indicating negative earnings. This financial metric, combined with the recent stock performance, has contributed to the negative evaluation of the stock. Over the past month, PHAT has returned -3.6%, and the stock has shown daily average volatility of 16.50% in the last week. Given these factors, no stop-loss is recommended for investors.